Codexis
Biosciences company applying synthetic chemistry technologies to create improved versions of small molecule therapeutics.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | $40.0m | Post IPO Debt | |
| Total Funding | 000k | ||
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 52 % | 32 % | (49 %) | (15 %) | 10 % | 23 % | 39 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (22 %) | (21 %) | (45 %) | (90 %) | (71 %) | (49 %) | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (20 %) | (24 %) | (109 %) | (110 %) | (89 %) | (59 %) | (15 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 53 % | 58 % | 84 % | 78 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Codexis, Inc. (Nasdaq: CDXS) is a leading protein engineering company that specializes in developing biocatalysts for the commercial manufacture of pharmaceuticals and fine chemicals. The company leverages its proprietary technology to create biocatalytic solutions that meet customer demands for rapid, cost-effective, and sustainable manufacturing processes. Codexis primarily serves pharmaceutical companies and chemical manufacturers, operating within the biotechnology and chemical industries. The business model focuses on the development and licensing of its biocatalysts, as well as providing custom enzyme development services. Revenue is generated through product sales, licensing agreements, and service contracts. Codexis is committed to innovation and sustainability, aiming to transform traditional manufacturing methods with its advanced protein engineering capabilities.
Keywords: protein engineering, biocatalysts, pharmaceuticals, fine chemicals, biotechnology, sustainable manufacturing, enzyme development, licensing, custom solutions, innovation.
